Threshold Pharmaceuticals, Inc. (THLD): A Biotech That Investors Need To Know About

Page 1 of 2

Biotech stocks can provide astronomical returns but also depressing losses. Before investing in these volatile stocks, investors need to understand the full picture, including fundamentals, technical, and upcoming catalysts. Below are 2 biotechs that appear to be well on their way to greatness.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is an early stage biotechnology company engaged in the discovery, development, and commercialization of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia. There is a lot to like about Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), including its recent trading action, fundamentals, partnerships, and upcoming business catalysts. The 2 year chart below shows the large trading move that the stock has seen.

The share price saw a large jump in early 2012 because of a flurry of positive press releases. Threshold announced a partnership with Merck KGaA (known as the “German Merck”.) Merck KGaA is very well known in Germany and is one of the largest biotechnology companies in Europe. The deal was extremely favorable for Threshold. Under the terms of the deal, Threshold received a $25 million upfront payment. Additionally, the company received a $20 million milestone payment based on positive results from its randomized Phase II clinical trial for pancreatic cancer. In total, the agreement gives Threshold the opportunity to earn up to $525 million in total milestone payments. The real bright spot of the deal is that Merck KGaA agreed to pay 70% of the worldwide development costs for TH-302. This means that investors will have to worry less about dilution than is normally typical for biotech companies of this size.

As mentioned above, this agreement is for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)’s therapy candidate called TH-302. TH-302 is being tested in multiple studies for the treatment of pancreatic cancer, soft tissue sarcoma, and other solid tumors. The two main trials for Threshold are TH-CR 406 and MAESTRO. TH-CR 406 is a Phase III clinical trial of TH-302 in combination with doxorubicin to treat patients with soft tissue sarcoma. MAESTRO is a Phase III clinical trial of TH-302 in combination with gemcitabine to treat patients with pancreatic cancer. The company is expected to release interim results of these trials in the fall this year with complete results expected in late 2014.

Fundamentally, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) also appears to be making great strides. For biotechs, cash is king. Threshold ended 2012 with $11 million in cash & cash equivalents and $59.8 million in short term investments for a total of $70.8 million. This was an increase of approximately $50 million from 2011 cash levels. Threshold also improved on the income statement by generating $5.9 million in revenue compared to just $62,000 for 2011.

Risks

Despite all of the above, it’s important for investors realize the potential downfalls to investing in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). First, the volatility for Threshold has been intense over the past 2 years. The share price traded as low $1.20 and as high as $9.28. It now trades at $5.48 and appears to have settled down but that will most likely change later this year once trial results are released. Second, the competition for pancreatic cancer therapies is intense. Celgene Corporation (NASDAQ:CELG) is heavily involved in this area with its potential therapy called Abraxane. In fact, just recently, the US Food and Drug Administration granted priority review for Abraxane. Celgene is seeking approval of Abraxane in combination with a product called Gemzar.. Should Abraxane receive approval, Celgene stands to gain a foothold on the market and potentially put Threshold in a catch up position. Additionally, Celgene Corporation (NASDAQ:CELG) could potentially be a tough opponent for Threshold based on its fundamentals. Analysts are expecting Celgene to show sales growth of 11.7% in 2013 and 14.5% in 2014. On top of that, Celgene was able to grow its year over year revenue by 13.5% from $4.84 billion to $5.5 billion. Celgene Corporation (NASDAQ:CELG) is not a company to be taken lightly and Threshold investors should understand this.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!